Keros Therapeutics, Inc. has recently announced its participation in two upcoming healthcare conferences. The company's Chair and Chief Executive Officer, Jasbir S. Seehra, Ph.D., will be presenting at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 10:30 a.m. Eastern time, and at the 7th Annual Evercore HealthConx Conference on December 4, 2024, at 3:00 p.m. Eastern time.
The company specializes in developing and commercializing novel therapeutics to treat patients with disorders related to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins. Keros is at the forefront of understanding the role of these proteins, which are crucial for the growth, repair, and maintenance of various tissues, including blood, bone, skeletal muscle, adipose, and heart tissue. Leveraging this understanding, Keros has discovered and is developing potential protein therapeutics, with its lead product candidate, elritercept (KER-050), aimed at treating low blood cell counts in patients with myelodysplastic syndromes and myelofibrosis.
Another product candidate, cibotercept (KER-012), is being developed for the treatment of pulmonary arterial hypertension and cardiovascular disorders, while the third product candidate, KER-065, is intended for the treatment of obesity and neuromuscular diseases.
Investors and stakeholders can access archived replays of the presentations on the company's website for up to 90 days following the conclusion of each event.
As a result of these announcements, the company's shares have moved 1.1% on the market, and are now trading at a price of $57.19. For the full picture, make sure to review Keros Therapeutics's 8-K report.
